ABSTRACT OBJECTIVES This study sought to examine the prevalence and predictors of influenza vaccination among participants in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study and investigate associations between receiving influenza vaccine and cardiovascular death or heart failure hospitalizations, all-cause hospitalizations, and cardiopulmonary or influenza-related hospitalizations.
I nfluenza infection can be devastating for patients with cardiovascular disease, and leads to significant morbidity and mortality each year (1-4).
Influenza vaccination is recommended annually for patients with cardiovascular disease by both the Centers for Disease Control and Prevention, the American Heart Association, and the European Center for Disease Prevention and Control (5,6). A meta-analysis of randomized, controlled studies has shown that receiving influenza vaccination reduced the risk for major adverse cardiovascular events in patients with coronary artery disease compared to no vaccination (7) .
Although widely recognized as beneficial, vaccination rates in patients with heart failure vary significantly in the United States and across the world (8) . Heart failure patients are especially susceptible to influenza-related complications including acute heart failure exacerbations and secondary infections such as pneumonia, both of which increase hospitalizations (4,9).
The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global
Mortality and Morbidity in Heart Failure) trial (10) enrolled patients with symptomatic heart failure with reduced ejection fraction and randomly allocated them to receive the angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) or enalapril. At the time of enrollment, participants were queried about receipt of influenza vaccination in the past 12 months. We used data from PARADIGM-HF to assess prevalence of and baseline factors associated with influenza vaccination, as well as outcomes in those who did and did not receive influenza vaccination. We hypothesized that influenza vaccination would be associated with reduced risk for hospitalizations and mortality in patients with heart failure after propensity adjustment.
METHODS STUDY DESIGN AND PATIENT SELECTION.
The PARADIGM-HF trial was a double blind, randomized, active controlled trial designed to assess the impact of the angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) compared with enalapril on cardiovascular mortality and heart failure hospitalizations in patients with left ventricular ejection fraction #40% and New York Heart Association (NYHA) functional class II to IV heart failure. Eligible subjects had elevated natriuretic peptide levels and were treated with stable doses of angiotensin- As an exploratory analysis, we used each country's percapita gross domestic product (GDP) as a continuous Vardeny et al. Table 1 . Influenza vaccine recipients were significantly older, had higher body mass index, lower NYHA functional class and eGFR, and were more likely to be male and Caucasian. More vaccine recipients had a history of diabetes, myocardial infarction, were taking beta-blockers, and had received cardiac resynchronization therapy, and less were taking mineralocorticoid receptor antagonists. There was significant variation in vaccination rates by country, with vaccination rates highest in the Netherlands (77.5%) the United Kingdom (77.2%), and Belgium (67.5%), and lowest in Asia (2.6%) ( Table 2) .
In a multivariable regression model, significant predictors of receiving influenza vaccine included, in descending order of association: country, older age, history of diabetes mellitus, lower NYHA functional class, lower heart rate, use of digoxin, use of an implantable cardioverter-defibrillator or cardiac resynchronization therapy, lower eGFR, higher ejection fraction, white race, and history of hospitalization for heart failure ( Table 3) . In an exploratory analysis, we observed a correlation between vaccination rates and country-specific GDP data (Online Figure 1) .
Influenza vaccination was associated with a lower risk for all-cause mortality compared to no 
DISCUSSION
In patients with heart failure and reduced ejection fraction enrolled in the PARADIGM-HF study, we found substantial worldwide regional variation in There are limited data on influenza vaccination rates in patients with heart failure worldwide. In the United States, influenza vaccination rates in patients with heart failure have ranged from 25% to approximately 76%, depending on the population studied (13-15). In one study of patients with heart failure who were mostly indigent or had Medicare or Medicaid, baseline rates were 28.3% prior to a vaccination campaign program, and improved to 50.3% after the program (14) . In an analysis of the impact of American Heart Association's Get With The Guidelines-Heart Failure "Plus" program, which recognized hospitals for additional quality measures such as influenza vaccination, the increase in influenza vaccination rates slowed following program implementation compared to years leading up to the program, although baseline vaccination rates were greater than 50% (13). The reasons for poor influenza vaccine uptake in the heart failure population remain unclear, but include factors such as reduced accessibility to vaccination clinics in rural areas, cost of Abbreviations as in Table 1 .
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Vardeny et al. Influenza vaccination was associated with a lower risk for all-cause death. In crude, but not propensity adjusted models, influenza vaccination was associated with a higher risk for hospitalizations.
Vardeny et al.
Influenza Vaccination and Heart Failure Vardeny et al. 
